Kupando
Sch├╢nefeld · Founded 2018
About Kupando
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: https://www.kupando.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/kupando-128802 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.